Eribulin Mesylate 0.5mg – Ebunat

Eribulin Mesylate 0.5mg (Ebunat) is a chemotherapy drug used for the treatment of metastatic breast cancer and liposarcoma. It is a microtubule inhibitor that disrupts cancer cell division, leading to apoptosis (cell death).

Composition & Form
Each vial of Ebunat contains 0.5mg of Eribulin Mesylate, formulated as an injectable solution for intravenous administration. This allows for precise dosing and rapid absorption in chemotherapy protocols.

Uses of Eribulin Mesylate 0.5mg

• Metastatic Breast Cancer: Approved for patients who have previously received at least two chemotherapy regimens, including anthracyclines and taxanes.
• Liposarcoma: Indicated for advanced or unresectable liposarcoma that has progressed despite prior treatment.

Mechanism of Action
Eribulin Mesylate functions by inhibiting microtubule dynamics, preventing cancer cells from completing cell division. This disruption leads to mitotic arrest and apoptosis, ultimately slowing tumor progression.

Dosage & Administration
The standard dosage for Eribulin Mesylate 0.5mg is administered as an intravenous infusion over 2-5 minutes on Days 1 and 8 of a 21-day cycle. Dosage may vary based on the patient’s body surface area, kidney function, and overall health status.

Side Effects
Common side effects of Ebunat include:

• Fatigue and weakness
• Low white blood cell counts (neutropenia)
• Nausea and vomiting
• Peripheral neuropathy
• Hair loss (alopecia)
• Constipation

Serious side effects such as severe neutropenia, cardiac complications, and hypersensitivity reactions should be reported to a healthcare provider immediately.

Precautions & Warnings

• Pregnancy & Breastfeeding: Can cause fetal harm; not recommended during pregnancy or breastfeeding.
• Blood Monitoring: Regular blood tests are required to monitor neutrophil levels and organ function.
• Drug Interactions: Inform your doctor about any medications, supplements, or herbal products you are taking.
• Storage: Store in a refrigerator at 2°C-8°C (36°F-46°F) and protect from light.

Why Choose Ebunat (Eribulin Mesylate 0.5mg)?

• Proven efficacy in treating metastatic breast cancer and liposarcoma.
• Short infusion time for patient convenience.
• Clinically tested and approved formulation.

Where to Buy Eribulin Mesylate 0.5mg – Ebunat?
This is available at certified oncology pharmacies and healthcare providers. Ensure you purchase from an authorized distributor to guarantee authenticity and quality.

Eribulin Mesylate 0.5mg (Ebunat) is an essential chemotherapeutic agent for patients with advanced breast cancer and liposarcoma. Proper medical supervision is required to ensure safe and effective use.

For more information, consult your oncologist.